Rohto PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 5/6
Rohto PharmaceuticalLtd has a total shareholder equity of ¥264.3B and total debt of ¥44.5B, which brings its debt-to-equity ratio to 16.8%. Its total assets and total liabilities are ¥408.3B and ¥143.9B respectively. Rohto PharmaceuticalLtd's EBIT is ¥36.8B making its interest coverage ratio -19.7. It has cash and short-term investments of ¥64.5B.
Key information
16.8%
Debt to equity ratio
JP¥44.54b
Debt
| Interest coverage ratio | -19.7x |
| Cash | JP¥64.50b |
| Equity | JP¥264.35b |
| Total liabilities | JP¥143.92b |
| Total assets | JP¥408.26b |
Recent financial health updates
These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Reasonably Well
Oct 20
Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?
Jul 11These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely
Apr 03Recent updates
Rohto PharmaceuticalLtd's (TSE:4527) Upcoming Dividend Will Be Larger Than Last Year's
Dec 06Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 15Rohto Pharmaceutical Co.,Ltd. (TSE:4527) Shares Could Be 25% Below Their Intrinsic Value Estimate
Nov 07These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Reasonably Well
Oct 20Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price
Oct 06Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down
Sep 22Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors
Aug 25Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next
Aug 11Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?
Jul 11Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Jun 23Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares
Jun 10Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward
May 14These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely
Apr 03Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching
Mar 21Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year
Mar 07Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Feb 26Financial Position Analysis
Short Term Liabilities: 4527's short term assets (¥204.9B) exceed its short term liabilities (¥111.1B).
Long Term Liabilities: 4527's short term assets (¥204.9B) exceed its long term liabilities (¥32.8B).
Debt to Equity History and Analysis
Debt Level: 4527 has more cash than its total debt.
Reducing Debt: 4527's debt to equity ratio has increased from 2.3% to 16.8% over the past 5 years.
Debt Coverage: 4527's debt is well covered by operating cash flow (88.6%).
Interest Coverage: 4527 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 23:25 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rohto Pharmaceutical Co.,Ltd. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitsuko Miyasako | Barclays |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |
| Hidemaru Yamaguchi | Citigroup Inc |